Cerba HealthCare S.A.S.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cerba HealthCare S.A.S. - overview
Established
1967
Location
-, -, France
Primary Industry
Healthcare
About
Cerba HealthCare S. A. S. , based in France, specializes in clinical pathology, providing diagnostic services that enhance preventive healthcare for a wide range of clients globally.
Cerba HealthCare S. A. S. operates primarily in clinical diagnostics, focusing on preventive healthcare services.
Founded in 1967 in France, the company has undergone strategic pivots and now serves clients across Europe, North America, and parts of Asia. The current CEO is Paul Navarre, with Philippe Buhl and Stephane GIDENNE also in leadership roles. The company has successfully raised EUR 1,800. 00 mn through 6 deals, with its most recent funding being a Secondary Buyout in March 2021, led by Partners Group and the Public Sector Pension Investment Board.
Cerba HealthCare specializes in clinical pathology, delivering a range of diagnostic services that enhance preventive healthcare. Its offerings include routine and specialized clinical pathology, clinical trials pathology, anatomo-cytopathology, medical imaging, and preventive testing. The company serves healthcare providers, research institutions, and laboratories across various global markets, ensuring accessibility and support for patients and clinicians alike. Cerba HealthCare generates revenue through structured transactions with healthcare providers and laboratories, primarily operating on a B2B model.
Clients are billed per test or service rendered, contributing to revenue from consistent demand for diagnostic services. The company's emphasis on precision medicine positions its pathology services as integral to the healthcare delivery system, aligning with its mission to promote preventive healthcare. Following its most recent deal in March 2021, Cerba HealthCare plans to utilize the acquired funds to innovate and expand its specialty in clinical trials and biotechnology services. The company aims to launch new products and enhance its offerings to meet evolving healthcare needs.
It is also targeting expansion into new geographical markets, which will further diversify its service accessibility and strengthen its position in the industry.
Current Investors
EQT, Public Sector Pension Investment Board, Partners Group
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Clinics/Outpatient Services
Website
www.cerbahealthcare.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Cerba HealthCare S.A.S. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | CIRION BioPharma Research Inc. | - | ||||||||
| Add-on | Completed | Vet-Histo | - | ||||||||
| Add-on, Trade Sale | Announced | Viroclinics Biosciences B.V. | - | ||||||||
| Add-on | Completed | Abich S.r.l. | - | ||||||||
| Add-on | Announced | Groupe Labexa | - |
Displaying 1 - 5 of 16
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.